[Federal Register Volume 60, Number 244 (Wednesday, December 20, 1995)]
[Notices]
[Page 65638]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-30944]



-----------------------------------------------------------------------


DEPARTMENT OF COMMERCE

Prospective Grant of Exclusive Patent License; Pasadena 
Scientific Industries

AGENCY: National Institute of Standards and Technology, Commerce.

ACTION: Notice of prospective grant of exclusive patent license.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institute of Standards and 
Technology (``NIST''), U.S. Department of Commerce, is contemplating 
the grant of a field of use exclusive license in the United States to 
practice the invention embodied in U.S. Patent Number 5,389,523, 
titled, ``Liposome Immunoanalysis By Flow Injection Assay'' to Pasadena 
Scientific Industries, having a place of business in Hanover, Maryland.

FOR FURTHER INFORMATION CONTACT: Bruce E. Mattson, National Institute 
of Standards and Technology, Technology Development and Small Business 
Program, Building 221, Room B-256, Gaithersburg, MD 20899.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be 
royalty-bearing and will comply with the terms and conditions of 35 
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be 
granted unless, within sixty days from the date of this published 
Notice, NIST receives written evidence and argument which establish 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    U.S. Patent Number 5,389,523 is a method of immunoanalysis which 
combines immobilized immunochemistry with the technique of flow 
injection analysis, and employs microscopic spherical structures called 
liposomes, or lipid vesicles, as carriers of detectable reagents.
    NIST may enter into a Cooperative Research and Development 
Agreement (``CRADA'') to perform further research on the invention for 
purposes of commercialization. The CRADA may be conducted by NIST 
without any additional charge to any party that licenses the patent. 
NIST may grant the licensee an option to negotiate for royalty-free 
exclusive licenses to any jointly owned inventions which arise from the 
CRADA as well as an option to negotiate for exclusive royalty-bearing 
licenses for NIST employee inventions which arise from the CRADA.
    The availability of the invention for licensing was published in 
the Federal Register, Vol. 57, No. 226 (November 23, 1992). A copy of 
the patent application may be obtained from NIST at the foregoing 
address.

    Dated: December 14, 1995.
Samuel Kramer,
Associate Director.
[FR Doc. 95-30944 Filed 12-19-95; 8:45 am]
BILLING CODE 3510-13-M